Osteoclast targeted therapy for prostate cancer: Bisphosphonates and beyond
- 29 June 2008
- journal article
- review article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 26 (4) , 420-425
- https://doi.org/10.1016/j.urolonc.2007.11.004
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid TumorsJNCI Journal of the National Cancer Institute, 2005
- A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal WomenJournal of Bone and Mineral Research, 2004
- Osteoporosis in men with prostate carcinoma receiving androgen‐deprivation therapyCancer, 2004
- Combined Analysis of Two Multicenter, Randomized, Placebo-Controlled Studies of Pamidronate Disodium for the Palliation of Bone Pain in Men With Metastatic Prostate CancerJournal of Clinical Oncology, 2003
- American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast CancerJournal of Clinical Oncology, 2003
- Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone and Placebo in Patients With Hormone-Refractory Prostate Cancer and PainJournal of Clinical Oncology, 2003
- Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study GroupJournal of Clinical Oncology, 2003
- Osteoclast differentiation and activationNature, 2003
- Comparative Tolerability of Drug Therapies for Hypercalcaemia of MalignancyDrug Safety, 1999
- Morphometric Evidence for Bone Resorption and Replacement in Prostate CancerBritish Journal of Urology, 1991